Evaluation of beta-cell autoantibodies as a disease marker and their relationship to glycemic control in diabetic patients

Evaluation of some autoantibodies as Glutamic acid decarboxylaseautoantibodies (GAD65 )and Islet cell autoantibodies(lCA) and insulinautoantibodies (IAA) as a disease markers and their relationship to certainresidual beta-cell function as well as glycemic control among diabetics.Also evaluation of the level of CD4+CD25+ out of CD4 (T - regulatorycells) among patients with immune mediated diabetes mellitus. ”This study was conducted on 80 subjects randomly selected fromthose attending Pediatrics and Internal Medicine out patients clinics 1The subjects classified into 3 group : First group(Group A) is thepatients group included 40, patients and is divided into: Adultgroup(Group AI) included 20 adult patients diagnosed as type II diabetesbut not responding to oral hypoglycemic medications their ages rangedfrom 20-60 years. Children group (Group A2) included 20 patientsdiagnosed as type I diabetes according WHO criteria their ages rangingfrom 3-16 years. Second group(Group B) is a risk group which is firstdegree relatives of diabetic parents this group included 20 healthyindividuals their ages ranging from 18-25 years. Third group, Controlgroup (Group C) included 20 subjects divided into: Group Cl (adultcontrol group) included 10 healthy adult subjects and Group C2 (childrenincluded 10 healthy children subjects.